Shuttle Pharmaceuticals Holdings, Inc. SHPH
Institutional shares held
276,445
0
calls
0
puts
Total value of holdings
$315K
$0
calls
$0
puts
Market Cap
$15.4M
13,467,300
Shares Out.
Institutional ownership
2.05%
# of Institutions
6
We take great care to ensure that the data presented and summarized in this overview for Shuttle Pharmaceuticals Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SHPH
View all-
Ayrton Capital LLC Westport, CT220KShares$251,2855.08% of portfolio
-
Two Sigma Securities, LLC New York, NY42.3KShares$48,2080.0% of portfolio
-
Virtu Financial LLC New York, NY12.7KShares$14,5280.0% of portfolio
-
Federation Des Caisses Desjardins Du Quebec Levis, A8500Shares$5700.0% of portfolio
-
Tower Research Capital LLC (Trc) New York, NY431Shares$4910.0% of portfolio
-
Bank Of America Corp Charlotte, NC56Shares$630.0% of portfolio
Latest Institutional Activity in SHPH
Top Purchases
Top Sells
About SHPH
Insider Transactions at SHPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 01
2024
|
Mira Jung Chief Scientific Officer |
SELL
Grant, award, or other acquisition
|
Direct |
598
-0.44%
|
$6,578
$11.28 P/Share
|
|
Mar 08
2024
|
Hoek Michael Vander Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+49.06%
|
-
|
|
Dec 13
2023
|
Milton Brown Director |
SELL
Open market or private sale
|
Direct |
2,921
-0.27%
|
$0
$0.46 P/Share
|
|
Dec 13
2023
|
Bette Jacobs Director |
SELL
Open market or private sale
|
Direct |
4,157
-13.31%
|
$0
$0.46 P/Share
|
|
Aug 14
2023
|
Anatoly Dritschilo CEO and Chairman |
BUY
Bona fide gift
|
Indirect |
2,100,000
+50.0%
|
-
|
|
Aug 14
2023
|
Anatoly Dritschilo CEO and Chairman |
SELL
Bona fide gift
|
Indirect |
2,100,000
-65.53%
|
-
|
|
Dec 29
2022
|
Chris Senanayake Director |
SELL
Open market or private sale
|
Direct |
1,626
-36.81%
|
$1,626
$1.6 P/Share
|
|
Dec 29
2022
|
Steven M Richards Director |
SELL
Open market or private sale
|
Direct |
995
-36.82%
|
$995
$1.6 P/Share
|
|
Dec 29
2022
|
Milton Brown Director |
SELL
Open market or private sale
|
Direct |
995
-0.09%
|
$995
$1.6 P/Share
|
|
Dec 29
2022
|
William Adkins |
SELL
Open market or private sale
|
Direct |
995
-0.54%
|
$995
$1.6 P/Share
|
|
Dec 29
2022
|
Bette Jacobs Director |
SELL
Open market or private sale
|
Direct |
4,366
-12.27%
|
$4,366
$1.6 P/Share
|
|
Dec 29
2022
|
Mira Jung Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
328
-0.03%
|
$328
$1.6 P/Share
|
|
Dec 29
2022
|
Tyvin Rich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,414
-36.79%
|
$1,414
$1.6 P/Share
|
|
Dec 29
2022
|
Anatoly Dritschilo CEO and Chairman |
SELL
Open market or private sale
|
Direct |
8,372
-0.77%
|
$8,372
$1.6 P/Share
|
|
Dec 29
2022
|
Peter Dritschilo President and COO |
SELL
Open market or private sale
|
Direct |
3,820
-36.8%
|
$3,820
$1.6 P/Share
|
|
Dec 29
2022
|
Hoek Michael Vander Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,243
-36.8%
|
$2,243
$1.6 P/Share
|
Last 12 Months Summary
Buy / Acquisition
100K
Shares
From
1
Insiders
| Grant, award, or other acquisition | 100K shares |
|---|
Sell / Disposition
7.68K
Shares
From
3
Insiders
| Grant, award, or other acquisition | 598 shares |
|---|---|
| Open market or private sale | 7.08K shares |